Clinical Trials · NCT05162768
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 102
- Start date
- Apr 2022
- Locations
- 32 sites, 10 countries
- Primary endpoint
- Six-minute walk test (6MWT)